Effect of intraoperative constant rate infusion of lidocaine on short-term survival of dogs with septic peritonitis: 75 cases (2007–2011)

Luca Bellini Department of Clinical Sciences and Services, The Royal Veterinary College, Hawkshead Ln, Hatfield, Hertfordshire AL9 7TA, England.

Search for other papers by Luca Bellini in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
and
Christopher J. Seymour Department of Clinical Sciences and Services, The Royal Veterinary College, Hawkshead Ln, Hatfield, Hertfordshire AL9 7TA, England.

Search for other papers by Christopher J. Seymour in
Current site
Google Scholar
PubMed
Close
 MA, VetMB

Abstract

OBJECTIVE To investigate whether intraoperative administration of a lidocaine infusion to dogs with septic peritonitis was associated with short-term (48 hours) survival after surgery.

DESIGN Retrospective case series.

ANIMALS 75 dogs with septic peritonitis.

PROCEDURES Medical records of dogs with septic peritonitis that underwent laparotomy between January 2007 and December 2011 at the Royal Veterinary College were reviewed. Select variables during the preoperative, intraoperative, and postoperative periods and short-term survival after surgery were compared between dogs that received an opioid only (group O; n = 33) and dogs that received lidocaine (50 μg/kg/min [22.7 μg/kg/min], IV; group L; 42) in addition to an opioid during surgery.

RESULTS The proportion of dogs that survived for 48 hours after surgery was significantly greater for group L (35/42) than for group O (20/33). Intraoperative infusion of lidocaine increased the odds of short-term survival (OR, 8.77; 95% CI, 1.94 to 39.57). No significant differences were observed between the 2 treatment groups for variables assessed during the preoperative and postoperative periods. During the intraoperative period, more dogs in group L received an IV bolus of a synthetic colloid than did dogs in group O, but the number of IV boluses administered was not associated with short-term survival.

CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that IV infusion of lidocaine might improve the short-term survival of dogs with septic peritonitis. Prospective clinical trials are necessary to determine the efficacy of lidocaine as a supportive treatment for dogs with septic peritonitis.

Abstract

OBJECTIVE To investigate whether intraoperative administration of a lidocaine infusion to dogs with septic peritonitis was associated with short-term (48 hours) survival after surgery.

DESIGN Retrospective case series.

ANIMALS 75 dogs with septic peritonitis.

PROCEDURES Medical records of dogs with septic peritonitis that underwent laparotomy between January 2007 and December 2011 at the Royal Veterinary College were reviewed. Select variables during the preoperative, intraoperative, and postoperative periods and short-term survival after surgery were compared between dogs that received an opioid only (group O; n = 33) and dogs that received lidocaine (50 μg/kg/min [22.7 μg/kg/min], IV; group L; 42) in addition to an opioid during surgery.

RESULTS The proportion of dogs that survived for 48 hours after surgery was significantly greater for group L (35/42) than for group O (20/33). Intraoperative infusion of lidocaine increased the odds of short-term survival (OR, 8.77; 95% CI, 1.94 to 39.57). No significant differences were observed between the 2 treatment groups for variables assessed during the preoperative and postoperative periods. During the intraoperative period, more dogs in group L received an IV bolus of a synthetic colloid than did dogs in group O, but the number of IV boluses administered was not associated with short-term survival.

CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that IV infusion of lidocaine might improve the short-term survival of dogs with septic peritonitis. Prospective clinical trials are necessary to determine the efficacy of lidocaine as a supportive treatment for dogs with septic peritonitis.

All Time Past Year Past 30 Days
Abstract Views 225 0 0
Full Text Views 1750 1364 77
PDF Downloads 625 228 20
Advertisement